Patents by Inventor Mouad Alami

Mouad Alami has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230285381
    Abstract: The present invention relates to compounds of formula (I); for use as peripheral NMDA receptor antagonists.
    Type: Application
    Filed: April 6, 2023
    Publication date: September 14, 2023
    Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITÉ PARIS-SACLAY, ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (APHP), HOPITAL MARIE LANNELONGUE
    Inventors: Sylvia COHEN-KAMINSKY, Marc HUMBERT, Sebastien DUMAS, Gilles BRU-MERCIER, Samir MESSAOUDI, Jean-Daniel BRION, Mouad ALAMI, Gilles GALVANI
  • Publication number: 20230203005
    Abstract: The present invention relates to the Compound of following formula (I): or a pharmaceutically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing such a compound and a method for preparing such a compound.
    Type: Application
    Filed: March 6, 2023
    Publication date: June 29, 2023
    Applicants: UNIVERSITE PARIS-SACLAY, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT GUSTAVE-ROUSSY, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Mouad ALAMI, Olivier PROVOT, Abdallah HAMZE, Ilhem KHELIFI, Timothée NARET, Sébastien APCHER, Romain DARRIGRAND
  • Patent number: 11634405
    Abstract: The present invention relates to the Compound of following formula (I): or a pharmaceutically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing such a compound and a method for preparing such a compound.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: April 25, 2023
    Assignees: UNIVERSITE PARIS-SACLAY PARC TECHNOLOGIQUE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT GUSTAVE-ROUSSY, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Mouad Alami, Olivier Provot, Abdallah Hamze, Ilhem Khelifi, Timothée Naret, Sébastien Apcher, Romain Darrigrand
  • Publication number: 20220280498
    Abstract: The present invention relates to compounds of formula (I): for use as peripheral NMDA receptor antagonists.
    Type: Application
    Filed: May 26, 2022
    Publication date: September 8, 2022
    Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE PARIS SUD, ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (APHP), HOPITAL MARIE LANNELONGUE
    Inventors: Sylvia COHEN-KAMINSKY, Marc HUMBERT, Sebastien DUMAS, Gilles BRU-MERCIER, Samir MESSAOUDI, Jean-Daniel BRION, Mouad ALAMI, Gilles GALVANI
  • Patent number: 11376245
    Abstract: The present invention relates to compounds of formula (I) for use as peripheral NMDA receptor antagonists.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: July 5, 2022
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE PARIS SUD, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS (APHP), HOPITAL MARIE LANNELONGUE
    Inventors: Sylvia Cohen-Kaminsky, Marc Humbert, Sebastien Dumas, Gilles Bru-Mercier, Samir Messaoudi, Jean-Daniel Brion, Mouad Alami, Gilles Galvani
  • Publication number: 20220047597
    Abstract: The present invention relates to the fields of medicine and in particular cancer treatment. The invention more specifically relates to new compounds which are typically for use as a medicament. In particular, the invention relates to the use of these new compounds for increasing the presentation, typically the production and presentation, of Pioneer Translation Products (PTPs)-derived antigens by cells, in particular cancer cells, or changing the immunopeptidome, in a subject, and inducing or stimulating an immune response in the subject. The present disclosure also relates to uses of such compounds, in particular to prepare a pharmaceutical composition and/or to allow or improve the efficiency of a therapy in a subject in need thereof. The invention also discloses methods for treating a disease, in particular cancer, for preventing or treating cancer metastasis and/or cancer recurrence, in a subject.
    Type: Application
    Filed: November 15, 2019
    Publication date: February 17, 2022
    Inventors: SÉBASTIEN APCHER, MOUAD ALAMI, ROMAIN DARRIGRAND, SAMIR MESSAOUDI, VALÉRIE SALGUES, ZAFIARISOA DOLOR RENKO, EXPEDITE YEN-PON
  • Patent number: 11247982
    Abstract: The present invention relates to the field of prevention and treatment of diseases involving NMDA receptors of the central nervous system. It relates more specifically to compounds of 1-(indol-3-yl)-3-hydroxy-3-(2-oxo-2-ethyl)-indol-2-ones type, as a drug, and the use of such compounds in the preparation of pharmaceutical compositions. These pharmaceutical compositions may in particular be intended to prevent or treat diseases involving NMDA receptors of the central nervous system, in particular severe/resistant epilepsy and cognitive disorders resulting therefrom, especially autism, but also strokes, schizophrenia, degenerative diseases involving the activation of NMDA receptors, such as Parkinson's disease and Alzheimer's disease, Rett syndrome, or amyotrophic lateral sclerosis, migraine, dementia and major depressive disorder.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: February 15, 2022
    Assignee: ADPUERIVITAM
    Inventors: Mouad Alami, Jean Daniel Brion, Samir Messaoudi, Sabrina Touchet, Gilles Galvani, Olivier Dulac, Svetlana Gataullina, Caroline Nous
  • Publication number: 20220023435
    Abstract: Disclosed are compounds having the formula (I): wherein R1 represents a group: —NH2, —NHCORa, —NHCOORb, —(C2-C6)alkenylene-CO—NH—OH, —(C2-C6)alkynylene-CO—NH—OH or —OH; R2 represents a group: —OCH3, —OCH2CH3, —SCH3, —SCH2CH3 or —OCHF2; R3 represents a hydrogen atom or a group: —CH3, —CN, —F, —Cl or —ORc; R4 represents a hydrogen atom or a group: —CH3, —CN, —F, —Cl or —ORd; Ra represents a group: —(C1-C5)alkyl or —CF3; Rb represents a group: —(C1-C5)alkyl or —CF3; Rc represents a group: —(C1-C5)alkyl or —CF3; and Rd represents a group: —(C1-C5)alkyl or —CF3; in the state of a base or acid or acid salts or base salts or in the form of hydrate or of solvate. Also disclosed are drug conjugates including such compounds.
    Type: Application
    Filed: September 17, 2019
    Publication date: January 27, 2022
    Inventors: Mouad ALAMI, Abdallah HAMZE, Olivier PROVOT, Ilhem KHELIFI, Vincent BLANCHARD, Nada MAKKY-IBRAHIM
  • Patent number: 11110105
    Abstract: The present invention relates to the fields of medicine and cancer treatment. The invention more specifically relates to new compounds which are typically for use as a medicament. In particular, the invention relates to the use of these new compounds for increasing the presentation, typically the production and presentation, of Pioneer Translation Products (PTPs)-derived antigens by cancer cells in a subject, and inducing or stimulating an immune response in the subject. The present disclosure also relates to uses of such compounds, in particular to prepare a pharmaceutical composition and/or to allow or improve the efficiency of a cancer therapy in a subject in need thereof. The invention also discloses methods for preventing or treating cancer, cancer metastasis and/or cancer recurrence in a subject. The present invention in addition provides kits suitable for preparing a composition according to the present invention and/or for implementing the herein described methods.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: September 7, 2021
    Assignee: INSTITUT GUSTAVE ROUSSY
    Inventors: Sébastien Apcher, Alison Pierson, Mathilde Boulpicante, Zafiarisoa Dolor Renko, Mouad Alami, Romain Darrigrand
  • Publication number: 20210230140
    Abstract: The present invention relates to the Compound of following formula (I): or a pharmaceutically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing such a compound and a method for preparing such a compound.
    Type: Application
    Filed: April 26, 2019
    Publication date: July 29, 2021
    Applicants: UNIVERSITE PARIS-SACLAY, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT GUSTAVE-ROUSSY, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Mouad ALAMI, Olivier PROVOT, Abdallah HAMZE, Ilhem KHELIFI, Timothée NARET, Sébastien APCHER, Romain DARRIGRAND
  • Patent number: 11014871
    Abstract: The present invention relates to the design of novel molecules, referred to as “multi-target” molecules, having a double pharmacophore and acting both as inhibitors of histone deacetylases (HDACs) and as inhibitors of tubulin polymerisation. The invention also describes the method for synthesising the “multi-target” molecules and their use in the treatment of cancer, a pharmaceutical composition comprising at least one “multi-target” molecule, and the use of such compositions in the treatment of cancer.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: May 25, 2021
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE PARIS-SUD
    Inventors: Mouâd Alami, Abdallah Hamze, Jean-Daniel Brion, Jérôme Bignon, Joëlle Dubois
  • Publication number: 20200385363
    Abstract: The present invention relates to the field of prevention and treatment of diseases involving NMDA receptors of the central nervous system. It relates more specifically to compounds of indole-1-yl-(1H)-quinoline-2-one and indole-3-yl-(1H)-quinoline-2-one type, as a drug, and the use of such compounds in the preparation of pharmaceutical compositions. These pharmaceutical compositions may in particular be intended to prevent or treat diseases involving NMDA receptors of the central nervous system, in particular severe/resistant epilepsy and cognitive disorders resulting therefrom, especially autism, but also strokes, schizophrenia, degenerative diseases involving the activation of NMDA receptors, such as Parkinson's disease and Alzheimer's disease, Rett syndrome, or amyotrophic lateral sclerosis, migraine, dementia and major depressive disorder.
    Type: Application
    Filed: May 29, 2018
    Publication date: December 10, 2020
    Inventors: Mouad Alami, Jean Daniel Brion, Samir Messaoudi, Sabrina Touchet, Gilles Galvani, Olivier Dulac, Svetlana Gataullina, Caroline Nous
  • Publication number: 20200297741
    Abstract: The present invention relates to the fields of medicine and cancer treatment. The invention more specifically relates to new compounds which are typically for use as a medicament. In particular, the invention relates to the use of these new compounds for increasing the presentation, typically the production and presentation, of Pioneer Translation Products (PTPs)-derived antigens by cancer cells in a subject, and inducing or stimulating an immune response in the subject. The present disclosure also relates to uses of such compounds, in particular to prepare a pharmaceutical composition and/or to allow or improve the efficiency of a cancer therapy in a subject in need thereof. The invention also discloses methods for preventing or treating cancer, cancer metastasis and/or cancer recurrence in a subject. The present invention in addition provides kits suitable for preparing a composition according to the present invention and/or for implementing the herein described methods.
    Type: Application
    Filed: April 11, 2018
    Publication date: September 24, 2020
    Inventors: SÉBASTIEN APCHER, ALISON PIERSON, MATHILDE BOULPICANTE, RENKO ZAFIARISOA DOLOR, MOUAD ALAMI, ROMAIN DARRIGRAND
  • Publication number: 20200253996
    Abstract: The present invention relates to the compounds of formula (I) below: wherein: X represents an oxygen atom, a sulfur atom, a nitrogen atom or a CH radical, The bond X—Y and Y are absent if X represents an oxygen or sulfur atom, the bond X—Y and Y are present if X represents a nitrogen atom or a CH radical, When present, Y represents a group R if X represents a nitrogen atom, a hydrogen atom or a group —NR1R2 if X represents a CH radical, (Het)Ar is an aromatic ring selected from the group consisting of aryl and heteroaryl groups, R3, R4, R5, R6 represent, independently of one another, a hydrogen atom, a halogen atom, a —NR12R13, a —SR14 group, a —OR14 group or a —CF3 group, When Y is —NR1R2, the groups —NR1R2 and (Het)Ar are in the cis-conformation, or a pharmaceutically acceptable salt thereof, for use in the treatment of proliferative diseases, infectious diseases, allergies, inflammation and/or asthma.
    Type: Application
    Filed: October 1, 2018
    Publication date: August 13, 2020
    Applicants: UNIVERSITE PARIS-SUD, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), INSTITUT GUSTAVE-ROUSSY
    Inventors: Samir MESSAOUDI, Mouad ALAMI, Jean-Daniel BRION, Amélie CHABRIER, Adam TELERMAN, Robert AMSON
  • Patent number: 10653694
    Abstract: The invention relates to compounds which are inhibitors of the polymerization of tubulin, to the methods for the production thereof, and to the uses of same.
    Type: Grant
    Filed: April 9, 2015
    Date of Patent: May 19, 2020
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE PARIS-SUD
    Inventors: Mouad Alami, Jean-Daniel Brion, Samir Messaoudi, Olivier Provot, Mohamed-Ali Soussi, Jerome Bignon, Joelle Dubois, Joanna Bakala-Wdzieczak
  • Patent number: 10538482
    Abstract: The present invention relates to cationic compounds of formula (I) for use as peripheral NMDA receptor antagonists.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: January 21, 2020
    Assignees: Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance Publique-Hopitaux de Paris, Centre National de la Recherche Scientifique (CNRS), Université Paris-Sud
    Inventors: Marc Humbert, Sylvia Cohen-Kaminsky, Sébastien Dumas, Gilles Bru-Mercier, Mouad Alami, Jean-Daniel Brion, Samir Messaoudi, Gilles Galvani
  • Publication number: 20190307738
    Abstract: The present invention relates to compounds of formula (I) for use as peripheral NMDA receptor antagonists.
    Type: Application
    Filed: June 13, 2017
    Publication date: October 10, 2019
    Applicants: Institut National de la Sante et de la Recherche Medicale (Inserm), Centre National de la Recherche Scientifique (CNRS), Universite Paris SUD, Assistance Publique-Hopitaux de Paris (APHP), Hopital Marie Lannelongue
    Inventors: Sylvia COHEN-KAMINSKY, Marc HUMBERT, Sebastien DUMAS, Gilles BRU-MERCIER, Samir MESSAOUDI, Jean-Daniel BRION, Mouad ALAMI, Gilles GALVANI
  • Publication number: 20190023645
    Abstract: The present invention relates to the design of novel molecules, referred to as “multi-target” molecules, having a double pharmacophore and acting both as inhibitors of histone deacetylases (HDACs) and as inhibitors of tubulin polymerisation. The invention also describes the method for synthesising the “multi-target” molecules and their use in the treatment of cancer, a pharmaceutical composition comprising at least one “multi-target” molecule, and the use of such compositions in the treatment of cancer.
    Type: Application
    Filed: January 5, 2017
    Publication date: January 24, 2019
    Applicants: UNIVERSITE PARIS-SUD, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Mouâd ALAMI, Abdallah HAMZE, Jean-Daniel BRION, Jérôme BIGNON, Joëlle DUBOIS
  • Publication number: 20180215699
    Abstract: The present invention relates to cationic compounds of formula (I) for use as peripheral NMDA receptor antagonists.
    Type: Application
    Filed: July 26, 2016
    Publication date: August 2, 2018
    Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance Publique-Hôpitaux De Paris, Centre National de la Recherche Scientifique (CNRS), Université Paris-Sud
    Inventors: Marc Humbert, Sylvia Cohen-Kaminsky, Sébastien Dumas, Gilles Bru-Mercier, Mouad Alami, Jean-Daniel Brion, Samir Messaoudi, Gilles Galvani
  • Publication number: 20170035761
    Abstract: The invention relates to compounds which are inhibitors of the polymerization of tubulin, to the methods for the production thereof, and to the uses of same.
    Type: Application
    Filed: April 9, 2015
    Publication date: February 9, 2017
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE PARIS-SUD
    Inventors: Mouad ALAMI, Jean-Daniel BRION, Samir MESSAOUDI, Olivier PROVOT, Mohamed-Ali SOUSSI, Jerome BIGNON, Joelle DUBOIS, Joanna BAKALA-WDZIECZAK